Eli Lilly Reduces Pricing on Key Obesity Treatment
Eli Lilly reduces the price of its obesity medication, Zepbound®, offering discounted single-dose vials to expand access for self-pay patients with an on-label prescription. Learn more about this cost-cutting initiative.
Eli Lilly Announces Tirzepatide Cuts Diabetes Risk by 94% in Three-Year Study
Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.
New Analysis Reveals Low Long-Term Adherence to GLP-1 Agonist Drugs for Weight Loss
New analysis reveals 85% of individuals stop using GLP-1 drugs for weight loss after two years. Learn about adherence trends and the role of fitness centers like Equinox and MIORA by Life Time in obesity management.
Ozempic and Other GLP-1 Agonists May Cut Cancer Risk in Obese Patients, Study Finds
Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.
Form Health Secures $38 Million Series B Funding to Enhance Obesity Care Services
Form Health, a leading provider of science-based obesity care in the U.S., secures $38 million in Series B funding to expand enterprise partnerships, hire ABOM-certified physicians, and enhance telehealth technology.
Walk This Way: How Your Genes Determine Your Steps to Avoid Obesity
Discover how genetics affect your exercise needs for obesity prevention. A groundbreaking study reveals why some need to walk more steps daily based on their genetic risk. Learn how personalized step counts can revolutionize obesity management.